Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Drugs Made In America Acquisition Corp. ( (DMAA) ).
Drugs Made in America Acquisition Corp. detailed compensation arrangements for its senior leadership tied to its future initial business combination. On April 22, 2026, the company updated its services agreement with Titan Advisory Services for Chief Financial Officer Saleem Elmasri, confirming unchanged monthly fees and recognizing accrued obligations, while increasing his prospective equity grant to 175,000 ordinary shares to be issued after a definitive deal is executed and the business combination closes.
Also on April 22, 2026, the company finalized a compensation agreement for Chief Executive Officer Roger Bendelac, appointed on February 28, 2026, setting monthly pay of $4,500 with a portion potentially deferred as an obligation of the company. Bendelac is additionally entitled to 250,000 ordinary shares, likewise contingent on execution of a definitive agreement and closing of the initial business combination, underscoring the company’s strategy of aligning leadership incentives with completing a transaction.
More about Drugs Made In America Acquisition Corp.
Drugs Made in America Acquisition Corp. is a special purpose acquisition company focused on completing an initial business combination. The company operates as a blank-check vehicle, raising capital to merge with or acquire operating businesses, and structures executive compensation partly around equity issuances tied to the successful closing of such a transaction.
Average Trading Volume: 198,847
Technical Sentiment Signal: Strong Buy
Current Market Cap: $355.5M
Find detailed analytics on DMAA stock on TipRanks’ Stock Analysis page.